Assisted Reproductive Technology (ART) Market Size & Share 2026 - 2035

Assisted Reproductive Technology Market Size

The global assisted reproductive technology (ART) market size was valued at around USD 38.9 billion in 2025 and is projected to grow from USD 41.4 billion in 2026 to USD 79.8 billion by 2035, expanding at a 7.6% CAGR from 2026 to 2035 during the forecast period, according to the latest report published by Global Market Insights Inc.

The increasing prevalence of infertility across global populations is a major growth driver for the market. According to the World Health Organization (WHO), in 2023, approximately 17.5% of the adult population, roughly 1 in 6 individuals worldwide, experience infertility. This statistic underscores the urgent need to expand access to affordable, high-quality fertility care. Top 5 players in this market areCooperCompanies, Vitrolife, Merck, Thermo Fisher Scientific and Hamilton Thorne.
 

The market grew from USD 32.8 billion in 2022 to USD 36.7 billion in 2024. The demand for fertility solutions translates to the constant demand for innovative and effective assisted reproduction technologies. Notably, demographic changes, which include the delay in the age of parenthood and the resulting lifestyles associated with the aged population, make natural conception difficult to achieve. According to the United Nations, the average age of first-time mothers continues to rise, with the majority of developed countries recording an average age of 30 years and above, thereby emphasizing the demand for assisted reproduction therapies. Additionally, increased awareness about the issues and solutions of infertility has also contributed to the demand for the product. Educational campaigns and government-backed initiatives are reducing stigma and promoting fertility health, particularly in emerging economies where urbanization and rising disposable incomes are expanding access to ART services. Increased awareness also calls for comprehensive counselling and training programs to ensure patients make informed decisions about treatment options.
 

Additionally, technological innovations in ART have significantly improved success rates and patient experience. Breakthroughs such as AI-driven embryo selection, time-lapse imaging, and genetic screening (PGT) are reducing cycle failures and enhancing implantation outcomes, making ART more effective and appealing to patients worldwide.
 

Assisted reproductive technology (ART) refers to a set of medical procedures and techniques used to help individuals or couples conceive a child when natural conception is difficult or impossible. These methods typically involve handling eggs, sperm, or embryos outside the body to achieve pregnancy.
 

Assisted Reproductive Technology Market Trends

• With advancements in the societal outlook and acceptance of assisted reproductive technology (ART), more people are resorting to these innovative technologies to deal with infertility problems. This has been largely driven by changes in attitudes toward building families, with variations becoming accepted.
   
• From then until now, there have been shifts and changes in the conventional perception of what constitutes a family, thus making way for single-parent and same-sex parents who will consider reproductive alternatives.
   
• For example, according to the Department of Health, State Government of Victoria (Australia), single male parent families are estimated to increase by 44% and 65% by 2041, while single female parent families are estimated to comprise 13% and 14% of the total number of families by that year. Going beyond, according to historical records, only fewer than 10% of families with children were single parents from the 1950s until 2022, when it is estimated to be 31%.
   
• This is coupled by the increasing recognition of ART by cultures and religions, thus increasing the usage of fertility services. People are currently seeking ways that suit their beliefs and, at the same time, provide remedies for challenges posed by infertilities. This is coupled by improvements in fertility testing technology and genetic screening, making the usage of ART easier and more successful.
   
• Facilitating regulatory environments and government initiatives regarding accessible infertility treatments, coupled with increasing insurance coverage, are propelling this trend forward. Collectively, such elements make up an excellent foundation for the adoption of ART.
   

Assisted Reproductive Technology Market Analysis

Based on product, the market is segmented into media, instrument, consumables and supplements. The media segment accounted for the market size of USD 13.7 billion in 2025 and is poised for significant growth at a CAGR of 7.9% during forecast period.
 

• The rising prevalence of infertility globally attributed to lifestyle changes, environmental factors, and delayed childbirth has led to a surge in ART procedures. For instance, according to the Japan Society of Obstetrics and Gynecology, the number of children born through IVF reached a record 69,797 in 2021, with the majority of treatments performed on women aged 39-41. This growing IVF volume directly translates into higher demand for specialized media formulations that optimize embryo viability and implantation success.
   
• Continuous technological advancements further strengthen this segment’s dominance. Innovations such as time-lapse imaging, preimplantation genetic testing (PGT), and embryo vitrification rely heavily on high-quality culture media to maintain cellular integrity and improve outcomes. As clinics strive to enhance success rates and minimize cycle failures, the adoption of premium media products becomes indispensable.
   
• Looking ahead, the media segment is expected to maintain its leadership position, supported by increasing ART procedure volumes, rising patient awareness, and ongoing research and development investments aimed at developing next-generation media tailored for personalized reproductive care.
   

Based on procedure, the assisted reproductive technology market is segmented into technology and type. The technology segment is further sub-segmented into in-vitro fertilization (IVF) and artificial insemination - intrauterine insemination (AI-IUI). The technology segment dominated the market with the largest revenue of USD 31.2 billion in 2025.
 

• Growing infertility prevalence, influenced by lifestyle changes, environmental factors, and delayed parenthood, has significantly increased demand for advanced reproductive solutions. Reflecting this trend, the Society for Assisted Reproductive Technology (SART) reported that in the U.S., the number of babies born through IVF rose from 91,771 in 2022 to 95,860 in 2023, accounting for 2.6% of all births. This surge underscores IVF’s critical role in modern family planning and its growing acceptance among diverse demographics.
   
• Technological advancements further reinforce this segment’s dominance. Innovations such as time-lapse embryo imaging, preimplantation genetic testing (PGT), and embryo vitrification have improved success rates and reduced cycle failures, making ART procedures more reliable and appealing. Additionally, the integration of AI-driven embryo selection and personalized treatment protocols is expected to enhance outcomes and patient confidence.
   
• As fertility clinics expand globally and supportive regulations improve access to treatment, the technology segment will continue to lead the ART market, driven by rising procedure volumes and continuous innovation.
   

Based on end use, the assisted reproductive technology market is segmented into hospitals, fertility clinics, cryobanks and other end users. The fertility clinics segment dominated the market with the largest revenue of USD 17.6 billion in 2025.
 

• These clinics specialize in reproductive medicine and employ highly trained professionals, including reproductive endocrinologists, embryologists, and fertility specialists, ensuring advanced care and successful outcomes for patients.
   
• The growing number of fertility clinics worldwide is a major driver of ART adoption. According to the National Institutes of Health, India has witnessed a surge in IVF facilities, with an estimated 2,500 clinics operational in 2023. Similarly, the National Library of Medicine reported that 601 fertility clinics in Japan performed ART treatments in 2021. This expansion improves accessibility, enabling more individuals and couples to seek treatment for infertility.
   
• In addition to infrastructure growth, clinics are increasingly integrating advanced technologies such as time-lapse embryo imaging, genetic screening, and AI-driven embryo selection, which enhance success rates and patient confidence. Combined with rising awareness and supportive regulations, these factors position fertility clinics as the primary end-use setting for ART procedures globally.
   

North America Assisted Reproductive Technology Market

• North America continues to lead the global market, supported by its advanced healthcare infrastructure, high awareness levels, and strong regulatory frameworks. A key growth driver is the rising prevalence of infertility across the region.
   
• For example, about 1 in 6 Canadian couples experience infertility, and 8% of couples where the female partner is aged 15-45 face fertility challenges, highlighting the growing need for accessible ART solutions.
   
• The region benefits from a well-established network of fertility clinics and significant investments in reproductive health services. Increasing adoption of cutting-edge technologies such as AI-driven embryo selection, genetic screening, and cryopreservation techniques further enhance success rates and patient confidence.
   
• Additionally, favorable insurance coverage and government initiatives aimed at improving access to infertility treatments are reducing financial barriers for patients.
   
• With continuous innovation, strong clinical expertise, and expanding treatment availability, North America is expected to maintain its dominant position in the global ART market throughout the forecast period.
   

The U.S. market was valued at USD 13 billion and USD 13.7 billion in 2022 and 2023, respectively. The market size reached USD 15.3 billion in 2025, growing from USD 14.4 billion in 2024.
 

• The U.S. remains a dominant force in the global assisted reproductive technology (ART) market, supported by advanced healthcare infrastructure and strong demand for fertility treatments. Rising infertility rates and delayed parenthood trends have significantly increased the need for ART services across the country.
   
• According to the Society for Assisted Reproductive Technology (SART), the total number of IVF cycles performed at 371 reporting clinics surged from 389,993 in 2022 to 432,641 in 2023, reflecting growing adoption of ART procedures nationwide.
   
• Additionally, the proportion of singleton births from IVF cycles remained exceptionally high at 96.74%, underscoring the effectiveness and safety of modern ART practices.
   
• This growth is further fueled by technological innovations such as AI-driven embryo selection, genetic screening, and time-lapse imaging, which enhance success rates and patient confidence. Combined with expanding fertility clinic networks and supportive insurance coverage, these advancements make ART more accessible and appealing to diverse patient groups.
   
• With continuous improvements in clinical outcomes and strong regulatory support, the U.S. is expected to maintain its leadership position in the global ART market throughout the forecast period.
   

Europe Assisted Reproductive Technology Market

Europe market accounted for USD 10.5 billion in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• Europe plays a pivotal role in the global market, supported by its advanced healthcare systems, strong public investment in reproductive health, and well-established regulatory frameworks. The region’s commitment to improving access to infertility treatments has driven widespread adoption of ART procedures across hospitals and fertility clinics.
   
• Infertility remains a significant challenge in Europe, affecting 1 in 6 couples of reproductive age, and in some countries, rates reach as high as 20%. This translates to approximately 25 million EU citizens requiring diagnosis and treatment for infertility. Additionally, changing social dynamics such as single women, same-sex couples, and individuals with genetic conditions seeking parenthood are expanding the patient base for ART services.
   
• In UK and other European countries, around 1 in 5 women reach age 45 without a child, with only 3% being childless by choice, highlighting the growing reliance on ART to achieve family-building goals. These demographic trends, combined with cultural acceptance and supportive legislation, are fuelling demand for advanced reproductive solutions.
   
• As societal norms evolve and technology adoption accelerates, Europe is expected to remain a key contributor to global ART market growth, driven by rising procedure volumes, supportive policies, and continuous innovation in reproductive medicine.
   

Germany dominates the Europe assisted reproductive technology market, showcasing strong growth potential.
 

• Germany represents a key segment of the European market, supported by its advanced healthcare infrastructure, strong regulatory framework, and growing demand for fertility treatments.
   
• The country faces persistent demographic challenges, with the total fertility rate falling to 1.35 children per woman in 2024, down from 1.38 in 2023, according to the Federal Statistical Office (Destatis). Although the pace of decline has slowed compared to previous years, the fertility rate remains well below the replacement level of 2.1, signaling continued reliance on ART solutions.
   
• This demographic trend, combined with delayed parenthood and lifestyle changes, is driving increased uptake of procedures such as in-vitro fertilization (IVF) and artificial insemination. With strong healthcare infrastructure, supportive policies, and rising awareness, Germany is expected to remain a leading contributor to Europe’s ART market growth, setting benchmarks for quality and innovation in reproductive medicine.
   

Asia Pacific Assisted Reproductive Technology Market

The Asia Pacific market is anticipated to grow at the highest CAGR during the analysis timeframe.
 

• The Asia-Pacific region, home to over half of the global population, is emerging as one of the fastest-growing markets for assisted reproductive technology (ART). However, the region faces structural population challenges due to declining fertility rates, driven by both diminished fertility desires and biological capacities.
   
• Lifestyle-related risk factors are contributing significantly to infertility. A study in India indicates that urban lifestyle factors such as diabetes and later age at first marriage are increasing infertility rates. Additionally, work-related stress and other stressful life events have been linked to menstrual irregularities, which can lead to polycystic ovary syndrome (PCOS) a major cause of infertility.
   
• According to the National Institutes of Health (NIH, 2024), obesity is a potent risk factor for polycystic ovary syndrome treatment (PCOS), further exacerbating infertility challenges across the region. These health trends, combined with delayed parenthood and rising awareness, are fueling demand for ART procedures such as in-vitro fertilization (IVF) and artificial insemination.
   
• With a vast population base, rising infertility prevalence, and accelerating adoption of advanced reproductive technologies, Asia-Pacific is poised to become a major driver of global ART market growth, offering immense opportunities for innovation and scalability.
   

China assisted reproductive technology market is anticipated to witness lucrative growth between 2026 to 2035.
 

• China represents one of the most critical markets for Assisted Reproductive Technology (ART) in Asia-Pacific, driven by demographic challenges and a sharp rise in infertility rates. The country’s declining birth rate and structural population issues have intensified the need for advanced reproductive solutions.
   
• According to the latest national reproductive health survey, China’s infertility rate surged from 12% in 2007 to 18% in 2020, meaning that one out of every 5.6 couples of childbearing age face difficulties conceiving. This rapid increase has placed additional pressure on healthcare systems and accelerated demand for ART procedures such as in-vitro fertilization (IVF) and artificial insemination.
   
• Contributing factors include urban lifestyle changes, delayed marriage, work-related stress, and rising prevalence of conditions such as PCOS and obesity, which are major causes of infertility. These trends, combined with cultural shifts and growing awareness, are driving more individuals and couples to seek fertility treatment.
   
• With its large population base, rising infertility prevalence, and growing acceptance of ART, China is expected to remain a key growth engine for the Asia-Pacific ART market, offering substantial opportunities for innovation and investment.
   

Latin America Assisted Reproductive Technology Market

Brazil leads the Latin America market, exhibiting remarkable growth during the analysis period.
 

• Brazil represents a key segment of the Latin American market, driven by its expanding healthcare infrastructure, growing urban population, and rising awareness of infertility treatments.
   
• The majority of ART services in Brazil are performed in the private sector, as these procedures are not covered by the Brazilian Unified Health System (SUS). This creates a strong market for private fertility clinics and specialized centers offering advanced reproductive solutions.
   
• Brazil currently has 193 assisted reproduction centers, reflecting steady growth in fertility care across the country. As a continental-sized developing nation, Brazil is evolving rapidly in the field of reproductive medicine, with clinics increasingly adopting technologies.
   
• Infertility prevalence, combined with delayed parenthood and lifestyle-related risk factors, is expected to further accelerate demand for ART services. With strong private sector participation and increasing investments in advanced fertility technologies, Brazil is positioned as a major growth engine for the Latin American ART market.
   

Middle East and Africa Assisted Reproductive Technology Market

The market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia is emerging as a strategic market for Assisted Reproductive Technology (ART) in the Middle East, driven by demographic shifts, rising infertility prevalence, and rapid healthcare modernization aligned with Vision 2030 goals.
   
• According to the General Authority for Statistics and reported by the National Institutes of Health (NIH, 2025), the country’s fertility rate has declined from 3.8 in 2011 to 2.7 in 2024 among Saudi females. This significant drop underscores changing family patterns and delayed parenthood, creating strong demand for advanced reproductive solutions.
   
• The healthcare transformation in Saudi Arabia emphasizes building new hospitals, specialized fertility clinics, and integrating cutting-edge technologies such as genetic screening, time-lapse embryo imaging, and cryopreservation to improve ART success rates.
   
• Additionally, growing cultural acceptance of ART, combined with government initiatives to expand private sector participation and improve access to infertility treatments, positions Saudi Arabia as a key growth engine for the Middle East ART market.
   
• With strong institutional support, rising healthcare investments, and increasing awareness of infertility solutions, Saudi Arabia is expected to play a central role in shaping regional ART adoption and innovation.
   

Assisted Reproductive Technology Market Share

The global market is shaped by a mix of established leaders and specialized players, creating a dynamic and highly regulated environment. The top five companies Hamilton Thorne, Thermo Fisher Scientific, Merck, Vitrolife, and CooperCompanies collectively account for approximately 17% of the global market share, driven by their comprehensive product portfolios, advanced technologies, and strong clinical partnerships.
 

To strengthen their market positions, these leading firms are pursuing multi-pronged strategies, including expanding fertility clinic networks, investing in AI-driven embryo selection and genetic screening technologies, and forming collaborations with healthcare providers and research institutions. Their focus on integrated solutions, such as time-lapse imaging systems, cryopreservation tools, and personalized treatment platforms, is enabling improved success rates, patient confidence, and operational efficiency.
 

Overall, the ART market is witnessing intensified competition and rapid technological innovation, as both established and emerging players scale their offerings to meet growing global demand for effective, safe, and accessible fertility solutions. With rising infertility prevalence and evolving societal norms, these strategic initiatives position top players to capture significant growth opportunities across developed and emerging regions.
 

Assisted Reproductive Technology Market Companies

Some of the eminent market participants operating in the assisted reproductive technology industry include:

• Esco Micro
• Gynotec
• Hamilton Thorne
• Indira IVF Hospital
• Ivy Fertility
• Kitazato
• Laboratoire
• Liverpool Partners Group
• Merck
• MISTRAL FERTILITY CLINICS
• NidaCon International
• The Cooper Companies
• Thermo Fisher Scientific
• Vitrolife Group
• Western Fertility Institute
   
• Hamilton Thorne

Hamilton Thorne specializes in advanced laboratory technologies for ART, including laser systems, sperm analysis tools, and AI-driven imaging. Its competitive edge lies in precision instruments that improve IVF efficiency and success rates.
 

• Thermo Fisher Scientific

Thermo Fisher offers a broad portfolio of ART lab solutions, from culture media and consumables to genetic testing platforms. Its strength is global reach and integration of cutting-edge technologies that support high-quality reproductive care.
 

• Merck

Merck stands out for its strong presence in fertility pharmaceuticals and lab reagents, backed by robust research and development capabilities. Its competitive advantage is delivering innovative solutions that enhance ART outcomes and patient safety.
 

Assisted Reproductive Technology Industry News:

• In January 2024, Ivy Fertility partnered with fertility specialty pharmacy SMP Pharmacy Solutions to enhance the patient experience across Ivy’s 13 fertility centers through a collaborative co-branding initiative. This strategic alliance aimed to optimize services and provide patients with comprehensive support, benefiting both companies through strengthened offerings and heightened patient satisfaction.
   
• In October 2023, Hamilton Thorne Ltd. acquired Gynetics Medical Products, N.V. and Gynetics Services B.V., a manufacturer of a diverse array of innovative and high-quality In-vitro fertilization (IVF) devices in the global IVF market. This strategic acquisition significantly expanded Hamilton Thorne's product offerings, strengthening its presence and competitiveness in the IVF industry.
   

The assisted reproductive technology market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Media
  • Embryo culture media
  • Cryopreservation media
  • Semen processing media
  • Ovum processing media
• Instrument
  • Vitrification devices
  • Incubators
  • Sperm analyzer system
  • Micromanipulators
  • Other instruments
• Consumables
  • Catheters
  • Needles
  • Storage containers
  • Other consumables
• Supplements

Market, By Procedure

• Technology
  • In-vitro fertilization (IVF)
    • IVF with intracytoplasmic sperm injection (ICSI)
    • IVF without ICSI
  • Artificial insemination - intrauterine insemination (AI-IUI)
• Type
  • Fresh donor
  • Fresh non donor
  • Frozen donor
  • Frozen non donor

Market, By End Use

• Hospitals
• Fertility clinics
• Cryobanks
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE